Our results indicated that the combination therapy comprising anti-PD1 and ASO PVT1 effectively eliminated CSCs to inhibit tumor growth and metastasis, and activated the tumor immune response to increase the recruitment of CD8+ T cells into tumor tissues. This evidence concerns the gene CD8A and neoplasm.